-

Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The TenoTac™ 2.0 Soft Tissue Fixation System uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surface.

Paragon 28’s CEO, Albert DaCosta, commented, “With the launch of TenoTac™ 2.0, we further refined our initial offering to allow surgeons greater control and precision to address the unique needs of each patient. TenoTac™ 2.0 adds to our growing portfolio of soft tissue products and the Hammertoe segment, with opportunities for significant improvements in patient outcomes.”

The addition of the TenoTac™ 2.0 Soft Tissue Fixation System bolsters Paragon 28’s hammertoe product offering, which includes the Paratrooper™ Plantar Plate System, HammerTube™ Hammertoe System, Mini-Monster® Screw System, and JAWS Staple System. With this comprehensive portfolio, Paragon 28® provides its customers innovative forefoot solutions to address flexible and rigid contractures of the lesser toes.

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Contacts

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
matt.bacso@gilmartinir.com

Paragon 28, Inc.

NYSE:FNA

Release Versions

Contacts

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
matt.bacso@gilmartinir.com

More News From Paragon 28, Inc.

Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle special...

Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (“Zimmer Biomet”). The expiration of the waiting period under the...

Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons (“AAOS”). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case man...
Back to Newsroom